We found a match
Your institution may have access to this item. Find your institution then sign in to continue.
- Title
The effect of subcutaneous methotrexate on markers of metabolic syndrome in psoriatic patients - preliminary report.
- Authors
Owczarczyk-Saczonek, Agnieszka; Drozdowski, Marek; Maciejewska-Radomska, Agata; Choszcz, Dariusz; Placek, Waldemar
- Abstract
Introduction: Methotrexate (MTX) has anti-proliferative and anti-inflammatory effects in psoriasis. Moreover, low doses can reduce the risk of developing cardiovascular diseases. It turns out that psoriasis and atherosclerosis have a similar pathogenetic mechanism: the same pro-inflammatory cytokines, Th1 and Th17, are involved in both diseases. Aim: To evaluate the effects of metabolic markers, protective cytokines (interleukin 10 (IL-10), transforming growth factor b (TGF-β)) and a marker of endothelial damage (endocan) in patients with plaque psoriasis. Material and methods: The study included 24 patients aged 27-69 years (9 female, 15 male) with plaque psoriasis. The metabolic syndrome according to the International Diabetes Federation (IDF) was evaluated. The laboratory tests were performed under fasting conditions: C-reactive protein (CRP), glucose, total cholesterol, triglycerides, high-density lipoprotein (HDL), uric acid, endocan, IL-10, and TGF-β. After 12 weeks of treatment with MTX injections 15 mg/week, every patient was assessed with the same laboratory tests. Results: After treatment we observed a statistically significant increase of endocan and IL-10, but no significant differences in the titer of TGF-β. C-reactive protein was reduced by approximately 54.7%. No improvement of lipid profile was observed, and even a significant increase in triglycerides was noted. Similarly, no significant difference was seen in the case of glucose and uric acid prior to and after treatment. Conclusions: Methotrexate in low doses in short-term treatment decreases CRP (anti-inflammatory effect) and increases endocan and IL-10 (potential protective role). Methotrexate is characterized by good efficacy and tolerability in therapy of patients with psoriasis.
- Subjects
METHOTREXATE; METABOLIC syndrome; BIOMARKERS; PSORIASIS; INTERLEUKIN-10; PATIENTS
- Publication
Advances in Dermatology & Allergology / Postępy Dermatologii i Alergologii, 2018, Vol 35, Issue 1, p53
- ISSN
1642-395X
- Publication type
Article
- DOI
10.5114/ada.2017.71358